
Merck's Dr Dave Maraldo explains that small-molecule platform agility and flexible conjugation capacity can help biologics manufacturing respond to research needs.
Wood CEO Ken Gilmartin gives his insight on what's currently in demand in terms of new bio/pharma manufacturing facilities.
Ken Gilmartin, CEO, Wood, gives his insight on what's currently in demand in terms of new bio/pharma manufacturing facilities. He emphasizes that a significant amount of capital is being invested in the United States for facilities, particularly in the large molecule and cell and gene therapy sectors.
For more INTERPHEX 2023 video content, check






